EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-HD-05(Investigational Cellular Protocol)
Clinical Overview & Biological Mechanism
Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent
The Pathology:
Huntington’s Disease (HD) is an autosomal dominant neurodegenerative genetic disorder caused by an expanded CAG trinucleotide repeat in the HTT gene. This produces toxic mutant huntingtin protein (mHTT), microglial activation, and selective loss of medium spiny projection neurons in the striatum (caudate and putamen).
The Cellular Mechanism:
Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily through paracrine signaling and neuro-immunomodulation:
- Secrete neurotrophic secretomes (BDNF, GDNF, VEGF) that support surviving striatal and cortical neurons.
- Downregulate chronically reactive microglia and reduce neurotoxic cytokines (TNF-α, IL-1β, IL-6).
- Reduce oxidative stress and mitochondrial metabolic strain in deep subcortical brain structures.
Investigational Intent:
This is an adjunctive, non-curative cellular intervention. It does not alter the underlying genetic mutation, clear mHTT protein aggregates, or regenerate dead striatal tissue; rather, it aims to reduce secondary neuroinflammation, support motor control, and enhance quality of life alongside standard multidisciplinary care.
Candidate Screening & Safety Triage
Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance
Eligible Profiles for Evaluation:
- Clinically and genetically confirmed Huntington’s Disease (documented CAG repeat expansion $\ge 36$).
- Early-to-moderate manifest stages (Unified Huntington's Disease Rating Scale / UHDRS Total Functional Capacity score $\ge 7$).
- Progressive chorea, motor incoordination, or gait unsteadiness despite standard symptomatic therapies (e.g., Tetrabenazine, Deutetrabenazine).
- Forced Vital Capacity (FVC) $\ge 60\%$ of predicted value; clinically cleared for international flights with a designated family caregiver.
Absolute Exclusion Criteria (Non-Candidates):
- Severe psychiatric instability, active psychosis, or acute unmanaged suicidal ideation (requires specialized psychiatric inpatient care).
- Late-stage bed-bound patients with severe dysphagia and high aspiration risk (requires gastroenterological feeding tube placement, not elective outpatient cell therapy).
- Active systemic infection, unmanaged malignancy, or acute cardiovascular instability.
Pre-Arrival Medical Clearance:
International candidates must submit genetic testing reports, brain MRI scans (striatal atrophy assessment), psychiatric evaluation/C-SSRS screening, pulmonary spirometry, and video recordings of gait and chorea for review by our multidisciplinary neurology board before travel booking.
Potential Improvements & Realistic Clinical Boundaries
Reported functional goals alongside documented non-responder rates and realistic limits
- Biological responses vary widely by disease stage, CAG repeat length, and baseline neurodegeneration. Stem cell therapy is adjunctive and cannot cure Huntington’s Disease; outcomes are never guaranteed.
Documented Clinical Realities:
Clinical Safety Profile & Anticipated Adverse Reactions
Anticipated transient reactions, procedural safeguards, and long-term surveillance
- Clinical-grade, unmanipulated allogeneic UC-MSCs maintain an established clinical safety record, but patients and caregivers must be aware of potential transient reactions:
Common & Transient (Days 1–3):
Low-grade post-infusion fever ($< 38^\circ\text{C}$ / $100.4^\circ\text{F}$), temporary fatigue, mild headache, or minor cannula site tenderness.
Rare Risks:
Allergic hypersensitivity reactions or blood pressure fluctuations (managed under continuous bedside vital sign and cardiac telemetry monitoring).
Step-by-Step Treatment Schedule & In-Hospital Workflow
Structured clinical itinerary during your stay in India (5 to 7 Days)
Day 1 (Comprehensive Hospital Workup):
- In-person evaluation by a movement disorder neurologist; baseline UHDRS motor score and Berg Balance Scale scoring.
None:
Days 2–3 (Cell Delivery & Supervised Rehabilitation):
- Monitored intravenous (IV) infusion of certified, viable UC-MSCs in sterile saline suspension.
Days 4–5 (Post-Infusion Assessment & Rest):
- Clinical review of vital stability, tolerance check, and issuance of a personalized home-rehabilitation protocol.
Day 6 (Discharge & Return Flight Clearance):
- Final neurological check and issuance of fit-to-fly documentation.
Longitudinal Remote Follow-Up:
Scheduled telemedicine consultations at Months 1, 3, 6, and 12, coordinated directly with your domestic neurologist.
Why Receive Care at Our Specialized Center in India?
Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability
- Neurogenetic & Movement Disorder Oversight: Protocols supervised directly by post-doctoral DM/DNB Neurologists and cellular biologists.
Transparent Pricing Scope:
Standard comprehensive packages range from $5,200 to $7,800 USD (inclusive of cellular biologicals, hospital daycare fees, physician consultations, and baseline routine tests). Detailed written estimates are provided prior to travel.
Treatment Costs & Comparative Package Inclusions
Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions
(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).
(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Specialized Centers) | $5,200 – $7,800 USD | 1 – 2 Weeks | NABH / JCI Accredited |
| United States | $35,000 – $65,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $28,000 – $55,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $32,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
Full medical concierge care, government visa assistance, and airport transit
Medical Visa (MED) Support:
Official hospital visa invitation letters issued within 24–48 hours for the patient and accompanying caregivers (with FRRO guidance).
Dedicated Case Coordinator:
A single English-speaking coordinator manages appointments, medical records, and hospital logistics.
Airport & Ground Transit:
Complimentary private airport pick-up/drop-off with dedicated wheelchair-accessible transport.
Language & Dietary Care:
Multi-language translators (Arabic, Russian, French) and access to customized meals (Halal, Vegetarian, Continental).
Logistics & Accessible Accommodation
Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers
Daycare Model:
Treatments occur in morning sessions, allowing the patient to rest in private quarters each afternoon to minimize sensory and choreic fatigue.
Direct Daily Commute:
Arranged transfers between local lodging and the medical center to prevent transit fatigue.
Regulatory Disclosures & Ethical Declarations
Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories
Investigational Therapy Notice:
Cell-based therapies for Huntington’s Disease are categorized as investigational cellular treatments under the National Guidelines for Stem Cell Research published by the Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO). They are not marketed as an approved routine standard of care or a definitive cure.
Ethical Standards:
All biological procurement follows informed maternal consent, donor screening, and statutory bioethics standards.
Peer-Reviewed Clinical Literature & Scientific Context
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Scientific Notice on Study Types:
Scientific Notice on Study Types: Huntington's Disease is a genetic condition with complex neuropathology. References 1 and 3 report on preclinical animal models and systematic meta-analyses assessing mesenchymal stem cell secretomes, BDNF delivery, and striatal preservation. Reference 2 cites a human phase 1 safety trial (Cellavita HD), and Reference 4 documents an observational registry protocol on ClinicalTrials.gov. These citations are provided to support informed discussions between families and their primary domestic neurologists.
Pollock et al. (Molecular Therapy / PubMed, 2016) — Preclinical BDNF Model
Pollock K, et al. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016; 24(5): 965–977. PubMed ID: PMID: 26765769 | PMCID: PMC4881765
Safety Evaluation of Cellavita HD (ClinicalTrials.gov Identifier NCT02728115)
Mesenchymal Stem Cell Therapy for Huntington Disease: A Meta-Analysis of Preclinical Evidence. Stem Cells Int / PMC; PMCID: PMC10164866.
Neurologic Stem Cell Treatment Study (NEST / ClinicalTrials.gov Identifier NCT02795052)
Neurologic Stem Cell Treatment Study (NEST) for Neurological and Neurodegenerative Disorders. National Library of Medicine / ClinicalTrials.gov; NCT02795052.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Huntington's Disease (HD)